Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

10417	Companies
218097	Keywords
147644	Articles
115404	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

PRESS RELEASE

published on 09/15/2025 at 16:45, 8 months 3 days ago

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Protagonist Therapeutics to present Phase 2b ANTHEM-UC study data on targeted oral peptide icotrokinra at UEGW Week 2025 in Berlin. Company focuses on advanced therapies in ulcerative colitis

Ulcerative Colitis Protagonist Therapeutics Icotrokinra Phase 2b ANTHEM-UC Study UEGW Week 2025
BRIEF

published on 09/11/2025 at 14:05, 8 months 7 days ago

Un acteur majeur sollicite l'approbation de l'EMA pour l'icotrokinra dans le traitement du psoriasis

Essais Cliniques Icotrokinra Psoriasis En Plaques Efficacité Du Traitement Demande D'admission À L'EMA
BRIEF

published on 09/11/2025 at 14:05, 8 months 7 days ago

Protagonist Seeks EMA Approval for Icotrokinra in Psoriasis

Clinical Trials Plaque Psoriasis Icotrokinra Treatment Efficacy EMA Application
PRESS RELEASE

published on 09/11/2025 at 14:00, 8 months 7 days ago

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Protagonist Therapeutics submits application to EMA for first approval of icotrokinra, an investigational targeted oral peptide blocking IL-23 receptor in plaque psoriasis treatment

Protagonist Therapeutics Plaque Psoriasis Treatment IL-23 Receptor Icoktrokinra EMA Submission
BRIEF

published on 08/26/2025 at 22:10, 8 months 23 days ago

Protagonist Therapeutics Engages in Key Investment Conferences

Clinical Trials Protagonist Therapeutics Investment Conferences Biopharmaceutical Development Icotrokinra And Rusfertide
BRIEF

published on 08/26/2025 at 22:10, 8 months 23 days ago

Protagonist Therapeutics participe à des conférences d'investissement clés

Essais Cliniques Thérapeutique Protagoniste Conférences D'investissement Développement Biopharmaceutique Icotrokinra Et Rusfertide
PRESS RELEASE

published on 08/26/2025 at 22:05, 8 months 23 days ago

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Protagonist Therapeutics announced CEO's participation in investment bank conferences in September. Company's advanced Phase 3 clinical development and future plans highlighted

Protagonist Therapeutics Phase 3 Clinical Development NDA Submission Investment Bank Conferences Drug Discovery Programs
BRIEF

published on 08/25/2025 at 13:05, 8 months 24 days ago

Le Rusfertide de Protagonist Therapeutics reçoit la désignation de thérapie révolutionnaire de la FDA

Rusfertide Thérapeutique Protagoniste Polyglobulie Vraie Thérapie Révolutionnaire Phase 3 VÉRIFIER
BRIEF

published on 08/25/2025 at 13:05, 8 months 24 days ago

Protagonist Therapeutics' Rusfertide Receives FDA Breakthrough Therapy Designation

Protagonist Therapeutics Rusfertide Polycythemia Vera Breakthrough Therapy Phase 3 VERIFY
PRESS RELEASE

published on 08/25/2025 at 13:00, 8 months 24 days ago

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Protagonist Therapeutics' rusfertide granted Breakthrough Therapy Designation by the FDA for polycythemia vera, complementing Orphan Drug and Fast Track designations. NDA filing on track for Q4

FDA Protagonist Therapeutics Rusfertide Breakthrough Therapy Designation NDA Filing

Accesswire

Published on 05/18/2026 at 22:30, 1 hour 19 minutes ago

Ondas Inc. Stockholders: Vote Now to Ensure Quorum for Annual Meeting
Published on 05/18/2026 at 14:37, 9 hours 12 minutes ago

Tyson Fury, The Gypsy King, Joins Datavault AI as International Spokesperson to Champion Athlete Data Monetization
Published on 05/18/2026 at 14:30, 9 hours 19 minutes ago

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
Published on 05/18/2026 at 08:01, 15 hours 48 minutes ago

Result of Fundraise
Published on 05/17/2026 at 15:20, 1 day 8 hours ago

China XLX Announces 2026 Q1 Results

View all ACCESSWIRE

EQS Group

Published on 05/18/2026 at 20:54, 2 hours 55 minutes ago

Freelance.com: chiffre d’Affaires 1er trimestre 2026 : 275,3 M€ (+4%)
Published on 05/18/2026 at 20:40, 3 hours 9 minutes ago

Aramco and Pasqal launch Saudi Arabia's first Quantum Computer and Middle East's first commercial Quantum Computing as a Service platform
Published on 05/18/2026 at 20:35, 3 hours 14 minutes ago

Africa Finance Corporation Approves US$100 Million Commitment to Africa-Focused Technology Fund Managers to Accelerate Africa’s Digital Industrialisation
Published on 05/18/2026 at 19:38, 4 hours 11 minutes ago

Holding(s) in Company
Published on 05/18/2026 at 19:00, 4 hours 49 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 11 MAI 2026 au 15 MAI 2026

Les Echos

Published on 05/18/2026 at 22:25, 1 hour 24 minutes ago

Résultats de l’offre publique de retrait et mise en œuvre du retrait obligatoire à venir sur les titres TERACT
Published on 05/18/2026 at 22:25, 1 hour 24 minutes ago

Results of the public buy-out offer and implementation of the subsequent squeeze-out of TERACT shares
Published on 05/18/2026 at 18:36, 5 hours 13 minutes ago

Déclaration des transactions sur actions propres réalisées du 11/05/2026 au 17/05/2026
Published on 05/18/2026 at 18:30, 5 hours 19 minutes ago

ALPOU - Groupe POULAILLON - Dépôt du projet de note en réponse à l'offre publique d'achat simplifiée
Published on 05/18/2026 at 18:23, 5 hours 26 minutes ago

260518 BENETEAU Transactions sur actions propres

View all LES ECHOS COMFI WIRE